ClinicalTrials.gg
CompletedNCT07055516RESOLVE-1Updated Sep 15, 2026

Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus

A Phase 2 interventional study of NT-0796 and Placebo in Obesity and Type 2 Diabetes, sponsored by Rezera (formerly NodThera Limited). Completed at 11 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Rezera (formerly NodThera Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes over a 6 months treatment period.

Read the detailed description

Potential participants will be screened within 28 days prior to baseline (Day 1), and eligible participants will be randomized 1:1:1 within each strata (T2DM or non-T2DM) to either NT-0796 twice daily (BID), NT-0796 once daily (QD) or placebo (BID). Study drug will be administered orally. Following 24 weeks of active treatment, participants will enter a 4-week safety follow-up before being discharged from the study. The primary endpoint of the study will be percentage weight change from baseline, the key-secondary endpoint will be change in HbA1c from baseline in the T2DM stratum, while secondary endpoints include DEXA scans, a variety of other relevant biometric measures as well as biomarkers. Pharmacokinetic, safety and tolerability as well as suicidality will also be assessed.

02

Conditions studied

  • Obesity and Type 2 Diabetes

Keywords

  • NLRP3
  • T2DM
  • NT-0796
  • Obesity
  • RESOLVE-1
  • Rezera Inc
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 176 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Rezera (formerly NodThera Limited) is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 75 years (inclusive) at screening who have signed and are willing and able to comply with the study protocol.
  • Have a of ≥30.0 kilogram/square meter (kg/m2) and \<40.0 kg/m2. (BMI values should be calculated to one decimal point precision and then assessed in terms of the required range.)
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.
  • Group 1: Have a diagnosis of T2DM, with \< 10% (86 mmol/mol) (measured at central lab during screening) and are on stable treatment for T2DM for at least 90 days prior to screening.
  • Group 2: No diagnosis or signs/symptoms of T2DM and HbA1c \< 6.5% (48 mmol/mol), measured at the central lab during screening.

Exclusion criteria

Exclusion Criteria:

  • T1DM, or a history of ketoacidosis, or hyperosmolar state/coma requiring hospitalization at any time prior to screening.
  • Have had 1 or more episode(s) of severe hypoglycemia in the 6 months prior to screening (Level 3 ADA 2025) defined as a severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycemia irrespective of glucose level, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms. Any participant that the investigator feels will not be able to communicate an understanding of hypoglycemic symptoms and the appropriate treatment of hypoglycemia should also be excluded.
  • History of stroke with residual neurological deficit within 2 years or within 6 months prior to Day 1.
  • History of acute coronary syndrome (ACS) including unstable angina, acute myocardial infarction (both ST segment elevation and non-ST segment elevation) within 6 months prior to Day 1.
  • Diagnosis of congestive heart failure (CHF) or clinical evidence suggesting CHF including history of orthopnea, exertional dyspnea, pedal edema, pulmonary rales, hepatosplenomegaly or cardiomegaly at the discretion of the Principal Investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Twice daily orally administered NT-0796 capsule

    Participants will receive study medication twice daily orally for up to 24 weeks, containing NT-0796 twice daily

    Drug: NT-0796

  • Experimental
    Once daily orally administered NT-0796 capsules and placebo second daily dose

    Participants will receive study medication twice daily orally for up to 24 weeks, containing NT-0796 once daily, with once daily placebo

    Drug: NT-0796 · Drug: Placebo

  • Placebo comparator
    Placebo orally administered capsule

    Participants will receive placebo twice daily orally for up to 24 weeks

    Drug: Placebo

Interventions

  • Orally administered capsules

  • DrugPlacebo

    Orally administered capsules

06

What researchers measure

Primary outcomes

  1. Ratio Change in hsCRP in participants with obesity and without T2DM hsCRP

    Time frame: Baseline to Week 24

  2. Change in body weight in participants with obesity with and without T2DM

    Time frame: Baseline to Week 24

Secondary outcomes

  1. HbA1c in participants with T2DM

    Time frame: Baseline to Week 24

  2. Change in body weight in participants with obesity with and without T2DM

    Time frame: Baseline to week 4, 8, 12, 16 and 20

  3. Change in waist circumference in participants with obesity with and without T2DM

    Time frame: Baseline to week 4, 8, 12, 16, 20 and 24

  4. Change in waist/height ratio in participants with obesity with and without T2DM

    Time frame: Baseline to week 4, 8, 12, 16, 20 and 24

  5. Incidence of body weight loss ≥5% in participants with obesity with and without T2DM

    Time frame: Baseline to Week 24

  6. Incidence of body weight loss ≥10% in participants with obesity with and without T2DM

    Time frame: Baseline to Week 24

  7. Incidence of body weight loss ≥15% in participants with obesity with and without T2DM

    Time frame: Baseline to Week 24

  8. Change in metabolic biomarker in participants with and without T2DM

    Time frame: Baseline to Week 24

  9. Ratio change from baseline in hsCRP

    Time frame: Weeks 4, 8, 12, 16, and 20

  10. Time-averaged ratio change from baseline in hsCRP

    Time frame: Between weeks 4 and 24.

  11. Time-to- achievement of hsCRP < 2mg/L in the subset of subjects > 2mg/L at baseline

    Time frame: Baseline to Week 24

  12. Ratio change from baseline in fibrinogen

    Time frame: Weeks 4, 8, 12, 16, 20 and 24.

  13. Change in lean mass as measured by Dual-energy Xray absorptiometry (DEXA) in participants with obesity with and without T2DM

    Time frame: Baseline to Week 24

  14. Change in bone mineral density as measured by Dual-energy Xray absorptiometry (DEXA) in participants with obesity with and without T2DM

    Time frame: Baseline to Week 24

  15. Incidence of adverse events in participants with obesity with and without T2DM

    Time frame: Baseline to Week 28

  16. Pharmacokinetics (PK); Area Under the Concentration vs. Time curve of NT0796 in participants with obesity with and without T2DM

    Time frame: Baseline to Week 24

  17. PK; Maximum Plasma Concentration (Cmax) of NT0796 in participants with obesity with and without T2DM

    Time frame: Baseline to Week 24

07

Study locations

11 sites
  • Investigative site
    Mesa, Arizona 85225, United States
  • Investigative site
    Los Angeles, California 90057, United States
  • Investigative site
    Cooper City, Florida 33024, United States
  • Investigative Site
    Hialeah, Florida 33016, United States
  • Investigative Site
    Jacksonville, Florida 32216, United States
  • Investigative Site
    Miami, Florida 33147, United States
  • Investigative Site
    Port Orange, Florida 32127, United States
  • Investigative Sites
    Marrero, Louisiana 70006, United States
  • Investigative Site
    Columbus, Ohio 43213, United States
  • Investigative Site
    Dallas, Texas 75230, United States
  • Investigative Site
    Manassas, Virginia 20110, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in May 2026, 12 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 12 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jul 9, 2025
StartActual
May 8, 2025
Primary completionActual
May 27, 2026
CompletionActual
May 27, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07055516
Lead sponsor
Rezera (formerly NodThera Limited)
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
May 8, 2025
Primary completion
May 27, 2026
Completion
May 27, 2026
Last update
Sep 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruvonoflast

Start the discussion